These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 8637518)

  • 21. Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.
    Spahn TW; Eugster HP; Fontana A; Domschke W; Kucharzik T
    Infect Immun; 2005 Nov; 73(11):7077-88. PubMed ID: 16239501
    [No Abstract]   [Full Text] [Related]  

  • 22. TNF, apoptosis and autoimmunity: a common thread?
    Beutler B; Bazzoni F
    Blood Cells Mol Dis; 1998 Jun; 24(2):216-30. PubMed ID: 9645922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the two TNF receptors in proliferation, NF-kappa B activation and discrimination between TNF and LT alpha signalling in the human myeloma cell line OH-2.
    Börset M; Medvedev AE; Sundan A; Espevik T
    Cytokine; 1996 Jun; 8(6):430-8. PubMed ID: 8818539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of TNF ligand and receptor family in the lymphoid organogenesis defined by gene targeting.
    Matsumoto M
    J Med Invest; 1999 Aug; 46(3-4):141-50. PubMed ID: 10687308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do tumor necrosis factor receptors work?
    Bazzoni F; Beutler B
    J Inflamm; 1995; 45(4):221-38. PubMed ID: 8867667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
    Younes A; Kadin ME
    J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha.
    Herr I; Posovszky C; Di Marzio LD; Cifone MG; Boehler T; Debatin KM
    Oncogene; 2000 Aug; 19(37):4255-62. PubMed ID: 10980599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRAIL and apoptosis induction by TNF-family death receptors.
    Wang S; El-Deiry WS
    Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Turning off follicular dendritic cells.
    Mackay F; Browning JL
    Nature; 1998 Sep; 395(6697):26-7. PubMed ID: 9738494
    [No Abstract]   [Full Text] [Related]  

  • 31. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines.
    Gibbons DL; Rowe M; Cope AP; Feldmann M; Brennan FM
    Eur J Immunol; 1994 Aug; 24(8):1879-85. PubMed ID: 8056047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of sphingomyelin cycle products in development of apoptosis mediated by Fas receptors and tumor necrosis factor alpha].
    Alesenko AV; Solov'ev AS; Terent'ev AA; Khrenov AV
    Izv Akad Nauk Ser Biol; 1998; (2):157-66. PubMed ID: 9609949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the TRAIL from p53 to apoptosis?
    Kastan M
    Nat Genet; 1997 Oct; 17(2):130-1. PubMed ID: 9326922
    [No Abstract]   [Full Text] [Related]  

  • 34. Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways.
    Mountz JD; Zhou T; Su X; Cheng J; Pierson M; Bluethmann H; Edwards CK
    Behring Inst Mitt; 1996 Oct; (97):200-19. PubMed ID: 8950477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of death receptor signaling in mechanical stretch-induced cardiomyocyte apoptosis.
    Liao X; Wang X; Gu Y; Chen Q; Chen LY
    Life Sci; 2005 May; 77(2):160-74. PubMed ID: 15862601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting death receptors in bladder, prostate and renal cancer.
    O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
    J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms.
    Boyle JJ; Weissberg PL; Bennett MR
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1553-8. PubMed ID: 12869351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ligands and receptors of the lymphotoxin system.
    Ware CF; VanArsdale TL; Crowe PD; Browning JL
    Curr Top Microbiol Immunol; 1995; 198():175-218. PubMed ID: 7774281
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines.
    Phillips TA; Ni J; Hunt JS
    Placenta; 2001; 22(8-9):663-72. PubMed ID: 11597186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.